Telomere-Maintenance Mechanisms in Soft-Tissue Malignant Fibrous Histiocytomas

Matsuo, Toshihiro; Shay, Jerry W.; Wright, Woodring E.; Hiyama, Eiso; Shimose, Shoji; Kubo, Tadahiko; Sugita, Takashi; Yasunaga, Yuji; Ochi, Mitsuo
April 2009
Journal of Bone & Joint Surgery, American Volume;Apr2009, Vol. 91-A Issue 4, p928
Academic Journal
Background: Sarcomas are distinct from carcinomas in that a substantial portion of them use the alternative lengthening of telomeres (ALT) mechanism to maintain their telomeres. The present study clarifies the prevalence of the ALT mechanism and examines the prognostic importance of telomere factors in soft-tissue malignant fibrous histiocytomas. Methods: We investigated a series of forty-three soft-tissue malignant fibrous histiocytoma samples from forty-three patients with regard to telomere length, telomerase activity, and human telomerase reverse transcriptase (hTERT) mRNA expression. Tumor samples were obtained from surgical specimens and were stored at -80°C until use. Univariate analysis of the tumor samples from patients for whom data were available on age, sex, histological grade, tumor size, surgical margin, recurrence, and telomere factors was performed with use of the log-rank test. Multivariate analysis with only significant variables was then performed. Results: Telomerase activity was detectable in 79.1% of the tumor samples, hTERT expression was demonstrated in 90.7% of the tumor samples, and evidence of engagement of the ALT mechanism of telomere length maintenance was observed in 32.6% of the tumor samples. Among the variables tested, ALT-positive status emerged as the only independent prognostic factor for death of the patient (hazard ratio, 0.275; 95% confidence interval, 0.104 to 0.724; p = 0.0089). There were no significant differences in survival rates between patients with ALT-positive, telomerase-positive tumors and those with ALT-positive, telomerase-negative tumors (p = 0.301) or between patients with ALT-positive tumors that showed above-average telomerase activity and those with ALT-positive tumors that showed below-average telomerase activity (p = 0.900). Therefore, telomerase activity does not affect the prognosis in patients with ALT-positive malignant fibrous histiocytoma. High telomerase expression is associated with a poor prognosis in patients with ALT-negative malignant fibrous histiocytoma (p = 0.0027). Conclusions: More detailed analysis will be needed to identify the most valuable prognostic factor in patients with malignant fibrous histiocytoma, and a more thorough understanding of telomere biology may give an indication of telomere-targeting therapy in the future. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.


Related Articles

  • Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1. Hunder, Naomi N.; Wallen, Herschel; Cao, Jianhong; Hendricks, Deborah W.; Reilly, John Z.; Rodmyre, Rebecca; Jungbluth, Achim; Gnjatic, Sacha; Thompson, John A.; Yee, Cassian // New England Journal of Medicine;6/19/2008, Vol. 358 Issue 25, p2698 

    We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine...

  • Antiangiogenic Therapy for Metastatic Breast Cancer: Current Status and Future Directions. Chan, Arlene // Drugs;2009, Vol. 69 Issue 2, p167 

    The use of chemotherapy and endocrine therapy have led to objective tumour shrinkage and improved survival in women with metastatic breast cancer. Despite the availability of many chemotherapeutic drugs, these agents do not act specifically on the various growth signalling pathways that drive...

  • UK audit highlights need for caution with chemotherapy in very sick patients. Mayor, Susan // BMJ: British Medical Journal (International Edition);11/15/2008, Vol. 337 Issue 7679, p1130 

    The article reports on the results of a study which was conducted by the UK National Confidential Enquiry into Patient Outcome and Death and which were published in November of 2008. Researchers reviewed the quality of care that was provided to more than 600 patients who received cancer...

  • Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin. Oosten, A. W.; Seynaeve, C.; Schmitz, P. I. M.; Den Bakker, M. A.; Verweij, J.; Sleijfer, S. // Sarcoma;2009, Vol. 2009, Special section p1 

    Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the...

  • Leiomyosarcomas of Vascular Origin in the Extremity. Abed, R.; Abudu, A.; Grimer, R. J.; Tillman, R. M.; Carter, S. R.; Jeys, L. // Sarcoma;2009, Vol. 2009, Special section p1 

    Between 1996 and 2006 a total of 278 patients with soft tissue Leiomyosarcoma were treated at our centre. We identified 16 patients (5.8%) where the tumour directly arose from the blood vessels. These tumours were studied to determine their prognosis and behaviour. All tumors were in the lower...

  • Primary Adult Renal Ewing's Sarcoma: A Rare Entity. Mukkunda, Ravindra; Venkitaraman, Ramachandran; Thway, Khin; Toon Min; Fisher, Cyril; Horwich, Alan; Judson, Ian // Sarcoma;2009, Vol. 2009, Special section p1 

    Background. Ewing’s sarcoma of extraskeletal origin is uncommon and that is of primary renal origin in adults are rare. There is no consensus on the optimal management of Ewing’s tumors of renal origin. Methods. A retrospective review of the clinical features, treatment, and...

  • The Value of Surgery for Retroperitoneal Sarcoma. Gholami, Sepideh; Jacobs, Charlotte D.; Kapp, Daniel S.; Parast, Layla M.; Norton, Jeffrey A. // Sarcoma;2009, Vol. 2009, Special section p1 

    Introduction. Retroperitoneal sarcomas are uncommon large malignant tumors. Methods. Forty-one consecutive patients with localized retroperitoneal sarcoma were retrospectively studied. Results. Median age was 58 years (range 20–91 years). Median tumor size was 17.5 cm (range 4–41...

  • Nonreferral of Possible Soft Tissue Sarcomas in Adults: A Dangerous Omission in Policy. Abellan, Juan F.; Lamo de Espinosa, José M.; Duart, Julio; Patiño-García, Ana; Martin-Algarra, Salvador; Martínez-Monge, Rafael; San-Julian, Mikel // Sarcoma;2009, Vol. 2009, Special section p1 

    Introduction. The aim of this study is to compare outcomes in three groups of STS patients treated in our specialist centre: patients referred immediately after an inadequate initial treatment, patients referred after a local recurrence, and patients referred directly, prior to any treatment....

  • Fungating Soft-Tissue Sarcomas. Potter, Benjamin K.; Adams, Sheila C.; Qadir, Rabah; Pitcher, J. David; Temple, H. Thomas // Journal of Bone & Joint Surgery, American Volume;Mar2009, Vol. 91-A Issue 3, p567 

    Background: Several variables have been reported as being prognostic with regard to the outcomes of soft-tissue sarcomas. Although the tumors are subjectively ominous, no prior study has been performed to evaluate the treatment or prognosis of fungating soft-tissue sarcomas. Methods: We...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics